Back to Search
Start Over
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
- Source :
-
The Journal of dermatological treatment [J Dermatolog Treat] 2020 Jun; Vol. 31 (4), pp. 359-365. Date of Electronic Publication: 2019 Apr 02. - Publication Year :
- 2020
-
Abstract
- Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. However, adverse events related to the immunosuppressive properties of these biologics have been observed. Methods: This review aims to synthesize and evaluate the literature investigating the risk of HZ in patients treated with IL-17 inhibitors, with a focus on psoriasis patients. We performed searches using the PubMED database with the following search terms: 'psoriasis,' 'herpes zoster,' 'secukinumab,' 'ixekizumab,' 'brodalumab,' 'IL-17,' 'anti-IL-17,' and 'safety.' Clinical trials, cohort studies, review articles, and meta-analyses were evaluated. Results: Studies did not detect a higher risk of HZ infections in psoriasis patients treated with IL-17 inhibitors when compared to those treated with placebo or other therapies. Studies of IL-17 inhibitors for other indications including psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and asthma yielded similar results. Conclusion: IL-17 inhibitors do not appear to increase risk of HZ. However, IL-17 inhibitors are relatively new medications, and further long-term data may be necessary to confirm this finding. Nevertheless, HZ vaccination should be considered on a case-bycase basis prior to initiating IL-17 therapy.
- Subjects :
- Antibodies, Monoclonal, Humanized adverse effects
Antibodies, Monoclonal, Humanized therapeutic use
Arthritis, Rheumatoid drug therapy
Biological Products adverse effects
Dermatologic Agents therapeutic use
Herpes Zoster
Humans
Immunosuppressive Agents therapeutic use
Spondylitis, Ankylosing drug therapy
Dermatologic Agents adverse effects
Immunosuppressive Agents adverse effects
Interleukin-17 antagonists & inhibitors
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1471-1753
- Volume :
- 31
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The Journal of dermatological treatment
- Publication Type :
- Academic Journal
- Accession number :
- 30900514
- Full Text :
- https://doi.org/10.1080/09546634.2019.1597246